A detailed history of Manufacturers Life Insurance Company, The transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 15,461 shares of OLMA stock, worth $141,777. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,461
Previous 15,888 2.69%
Holding current value
$141,777
Previous $171,000 7.6%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.41 - $16.46 $4,445 - $7,028
-427 Reduced 2.69%
15,461 $184,000
Q2 2024

Aug 14, 2024

BUY
$8.73 - $13.99 $47,569 - $76,231
5,449 Added 52.2%
15,888 $171,000
Q1 2024

May 14, 2024

SELL
$10.95 - $16.62 $5,332 - $8,093
-487 Reduced 4.46%
10,439 $118,000
Q4 2023

Feb 13, 2024

SELL
$10.53 - $17.14 $9,434 - $15,357
-896 Reduced 7.58%
10,926 $153,000
Q3 2023

Nov 15, 2023

SELL
$8.19 - $12.98 $368 - $584
-45 Reduced 0.38%
11,822 $146,000
Q2 2023

Aug 11, 2023

SELL
$3.22 - $9.65 $1,181 - $3,541
-367 Reduced 3.0%
11,867 $107,000
Q2 2022

Aug 15, 2022

SELL
$2.04 - $4.61 $24,957 - $56,398
-12,234 Closed
0 $0
Q1 2022

Aug 11, 2023

BUY
$3.89 - $9.43 $47,590 - $115,366
12,234 New
12,234 $52,000
Q1 2022

May 20, 2022

SELL
$3.89 - $9.43 $7,846 - $19,020
-2,017 Reduced 14.15%
12,234 $52,000
Q4 2021

Feb 16, 2022

BUY
$8.75 - $30.71 $8,907 - $31,262
1,018 Added 7.69%
14,251 $133,000
Q3 2021

Nov 12, 2021

BUY
$22.96 - $30.13 $136,405 - $179,002
5,941 Added 81.47%
13,233 $365,000
Q2 2021

Aug 12, 2021

BUY
$21.15 - $36.14 $9,496 - $16,226
449 Added 6.56%
7,292 $204,000
Q1 2021

May 03, 2021

BUY
$27.81 - $53.64 $190,303 - $367,058
6,843 New
6,843 $227,000

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $371M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.